Skip to main content
Caplight Logo









METHYS Dx

METHYS Dx

Private
ParisHealthcare & Life Scienceshttps://methysdx.com/

Last Round

Crowdfunding

May 13, 2026

Est. Valuation

$7.87M

Total Funding Raised

$1.73M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

METHYS Dx is a biotechnology company that develops personalized medicine solutions for oncology through non-invasive liquid biopsy monitoring techniques.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

DNA methylationepigenetic biomarkersmolecular diagnosticscancer diagnosticsliquid biopsyprecision medicinelaboratory developed testsLDTdigital PCRbiotech R&Depigeneticsdiagnostic assaysearly cancer detectionclinical trial servicesbiomarker discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

METHYS Dx Comparables

Compare METHYS Dx with similar companies based on industry and business-model similarity.

METHYS Dx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alercell, Inc.
83%
Harbinger Health
79%
Precision Epigenomics
78%

METHYS Dx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingMay 13, 2026
GrantJul 5, 2023
Pre SeedMay 1, 2023

Key People

Founding team and executive leadership

Magali Droniou

CEO, COO

Executive Team

Antoine Masurier

CTO

Executive Team

Muriel Jeannot

Directeur administratif et financier - DAF - CFO

Executive Team

METHYS Dx Investors

Notable investors and investment history

METHYS Dx investors
InvestorRounds
ErganeoPre Seed
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    Grew 26% QoQ from 19 to 24 employees.

  • Jul 20, 2026

    Grew 16% QoQ, from 19 to 22 employees.

METHYS Dx Filings

Explore SEC and related filing metadata, where available.

METHYS Dx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about METHYS Dx's valuation, stock price, and market status.

Is METHYS Dx a public or private company?

METHYS Dx is a private company.

What is the current stock price of METHYS Dx?

METHYS Dx is a private company with no public stock price. Caplight tracks METHYS Dx's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is METHYS Dx worth (valuation)?

METHYS Dx's valuation is estimated at $7.9M based on funding round data.

Can I buy METHYS Dx stock?

METHYS Dx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was METHYS Dx's last funding round?

METHYS Dx's most recent funding round was Crowdfunding on May 13, 2026.

Who are the main investors in METHYS Dx?

Key investors in METHYS Dx include Erganeo, Bpifrance.

Will METHYS Dx IPO soon?

No public IPO plans have been announced for METHYS Dx.

How can I track METHYS Dx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor METHYS Dx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range18
Year Founded2021
Last FundingMay 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?